Evidence map›Paper›PMID 27799767›Full record

ArticleInternational journal of nanomedicine

Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.

Yi Zhou, Ruju Wang, Bing Chen, Dan Sun, Yong Hu, Peipei Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2020
    Review
  7. Article
  8. Gambogic Acid as a Candidate for Cancer Therapy: A Review.International journal of nanomedicine · 2020
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Yi ZhouDepartment of Hematology, Drum Tower Hospital, School of Medicine; Institute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of Engineering and Applied Sciences, Nanjing University, Nanjing People's Republic of China.
Ruju WangDepartment of Hematology, Drum Tower Hospital, School of Medicine.
Bing ChenDepartment of Hematology, Drum Tower Hospital, School of Medicine.
Dan SunSchool of Mechanical Engineering, Queen's University Belfast, Belfast, UK.
Yong HuInstitute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of Engineering and Applied Sciences, Nanjing University, Nanjing People's Republic of China.
Peipei XuDepartment of Hematology, Drum Tower Hospital, School of Medicine.
Nanjing Drum Tower Hospital · CNNanjing University · CNQueen's University Belfast · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To minimize the side effects and the multidrug resistance (MDR) arising from daunorubicin (DNR) treatment of malignant lymphoma, a chemotherapy formulation of cysteamine-modified cadmium tellurium (Cys-CdTe) quantum dots coloaded with DNR and gambogic acid (GA) nanoparticles (DNR-GA-Cys-CdTe NPs) was developed. The physical property, drug-loading efficiency and drug release behavior of these DNR-GA-Cys-CdTe NPs were evaluated, and their cytotoxicity was explored by 3-[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide assay. These DNR-GA-Cys-CdTe NPs possessed a pH-responsive behavior, and displayed a dose-dependent antiproliferative activity on multidrug-resistant lymphoma Raji/DNR cells. The accumulation of DNR inside the cells, revealed by flow cytometry assay, and the down-regulated expression of P-glycoprotein inside the Raji/DNR cells measured by Western blotting assay indicated that these DNR-GA-Cys-CdTe NPs could minimize the MDR of Raji/DNR cells. This multidrug delivery system would be a promising strategy for minimizing MDR against the lymphoma.

Indexed as

AnimalsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cadmium CompoundsCell Line, TumorCysteamineDaunorubicinDose-Response Relationship, DrugDrug LiberationDrug Resistance, MultipleFemaleHumansHydrogen-Ion ConcentrationLymphomaMaleMiceAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cadmium Compoundscadmium tellurideCysteamineDaunorubicingambogic acidTelluriumXanthonesCys-CdTe QDsdaunorubicingambogic acidmultidrug resistancenon-Hodgkin’s lymphoma

Identifiers

PMID27799767
PMCPMC5077128
OpenAlexW2535091642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.